BioSpace News Archive

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its Meridian ALIF (anterior lumbar interbody fusion) System and Reef A interbody with NanoMetalene® surface technology

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the appointment of Dr. Jennifer Gudeman to the newly formed role of Vice President, Medical and Clinical Affairs

Bilayer tablet patent application could provide U.S. patent coverage for Iterum’s commercial formulation through 2039, if granted

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the SCYNEXIS’s New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC), also known as vaginal yeast infections

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the ongoing Phase 1/2 CIRLL (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma) clinical trial, in which cirmtuzumab, an investigational anti-ROR1 monoclonal antibody,

NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that they have met the 165 patient enrollment target agreed with the U.S. Food and Drug Administration in the ongoing phase 2b/3 trial of RLF-100™ for treating Respiratory Failure in patients with Critical COVID-19.

Increased cases of colorectal cancer across the globe are predicted to drive sales opportunities in the global fecal immunochemical diagnostic tests market during the assessment period of 2020 to 2030.

Viral RNA extraction kit refers to an important indicator for the purpose of separation of trace amounts of viral RNA from given samples together with body fluids, plasma, serum, and blood.

Increasing cases of cancers in all worldwide locations is estimated to boost sales opportunities in the global non-invasive cancer therapies market during the tenure of 2020 to 2030.

Optic nerve disorder is widely known as optic neuropathy, which is medical condition indicating at a gradual degeneration of the optic nerve.